Cargando…

NOT-Gated CD93 CAR T Cells Effectively Target AML with Minimized Endothelial Cross-Reactivity

Chimeric antigen receptor (CAR) T cells hold promise for the treatment of acute myeloid leukemia (AML), but optimal targets remain to be defined. We demonstrate that CD93 CAR T cells engineered from a novel humanized CD93-specific binder potently kill AML in vitro and in vivo but spare hematopoietic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Richards, Rebecca M., Zhao, Feifei, Freitas, Katherine A., Parker, Kevin R., Xu, Peng, Fan, Amy, Sotillo, Elena, Daugaard, Mads, Oo, Htoo Zarni, Liu, Jie, Hong, Wan-Jen, Sorensen, Poul H., Chang, Howard Y., Satpathy, Ansuman T., Majzner, Robbie G., Majeti, Ravindra, Mackall, Crystal L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2021
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8580619/ https://www.ncbi.nlm.nih.gov/pubmed/34778803 http://dx.doi.org/10.1158/2643-3230.BCD-20-0208

Ejemplares similares

Oncofetal Chondroitin Sulfate: A Putative Therapeutic Target in Adult and Pediatric Solid Tumors
por: Khazamipour, Nastaran, et al.
Publicado: (2020)

c-Jun overexpression in CAR T cells induces exhaustion resistance
por: Lynn, Rachel C., et al.
Publicado: (2019)

CAR T Cell Therapy for Neuroblastoma
por: Richards, Rebecca M., et al.
Publicado: (2018)

Dynamic chromatin regulatory landscape of human CAR T cell exhaustion
por: Gennert, David G., et al.
Publicado: (2021)

Transient “rest” restores functionality in exhausted CAR-T cells via epigenetic remodeling
por: Weber, Evan W., et al.
Publicado: (2021)

Hepatoma-derived growth factor-related protein 2 promotes DNA repair by homologous recombination
por: Baude, Annika, et al.
Publicado: (2016)

Immune-Based Approaches for the Treatment of Pediatric Malignancies
por: Bosse, Kristopher R., et al.
Publicado: (2020)

Identification of dual positive CD19+/CD3+ T cells in a leukapheresis product undergoing CAR transduction: a case report
por: Schultz, Liora, et al.
Publicado: (2020)

Internalization and trafficking of CSPG-bound recombinant VAR2CSA lectins in cancer cells
por: Wang, Chris Kedong, et al.
Publicado: (2022)

Inosine Induces Stemness Features in CAR T cells and Enhances Potency
por: Klysz, Dorota D., et al.
Publicado: (2023)

FOXO1 is a master regulator of CAR T memory programming
por: Doan, Alexander, et al.
Publicado: (2023)

Potent antitumor efficacy of anti-GD2 CAR T-cells in H3K27M+ diffuse midline gliomas
por: Mount, Christopher W., et al.
Publicado: (2018)

Real-time and label free determination of ligand binding-kinetics to primary cancer tissue specimens; a novel tool for the assessment of biomarker targeting
por: Clausen, Thomas Mandel, et al.
Publicado: (2016)

Convergent Epigenetic Evolution Drives Relapse in Acute Myeloid Leukemia
por: Nuno, Kevin A., et al.
Publicado: (2023)

CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL
por: Fry, Terry J., et al.
Publicado: (2017)

An LSC epigenetic signature is largely mutation independent and implicates the HOXA cluster in AML pathogenesis
por: Jung, Namyoung, et al.
Publicado: (2015)

A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma
por: Ramos, Louise, et al.
Publicado: (2023)

Emerging CAR T Cell Strategies for the Treatment of AML
por: Vishwasrao, Paresh, et al.
Publicado: (2022)

The Black Hole: CAR T Cell Therapy in AML
por: Atilla, Erden, et al.
Publicado: (2023)

Homology-independent targeted insertion (HITI) enables guided CAR knock-in and efficient clinical scale CAR-T cell manufacturing
por: Balke-Want, Hyatt, et al.
Publicado: (2023)

Biomarkers as targets for CAR-T/NK cell therapy in AML
por: Shao, Ruonan, et al.
Publicado: (2023)

NRD1, which encodes nardilysin protein, promotes esophageal cancer cell invasion through induction of MMP2 and MMP3 expression
por: Uraoka, Naohiro, et al.
Publicado: (2014)

Autophagy mediates proteolysis of NPM1 and HEXIM1 and sensitivity to BET inhibition in AML cells
por: Huang, Min, et al.
Publicado: (2016)

CD70 CAR T cells in AML: Form follows function
por: Mirazee, Justin, et al.
Publicado: (2022)

ALK (anaplastic lymphoma kinase, CD246)-specific CARs: new immunotherapeutic agents for the treatment of pediatric solid tumors
por: Orentas, Rimas J, et al.
Publicado: (2013)

In vivo imaging of nanoparticle-labeled CAR T cells
por: Kiru, Louise, et al.
Publicado: (2022)

Targeting high-risk pediatric solid tumors with CAR T cells directed against ALK (anaplastic lymphoma kinase, CD246)
por: Walker, Alec, et al.
Publicado: (2014)

Dual-inhibitory domain iCARs improve the efficiency of the AND-NOT gate CAR T strategy
por: Bangayan, Nathanael J., et al.
Publicado: (2023)

MicroRNA-148a is downregulated in gastric cancer, targets MMP7, and indicates tumor invasiveness and poor prognosis
por: Sakamoto, Naoya, et al.
Publicado: (2014)

Evaluation of switch-mediated costimulation in trans on universal CAR-T cells (UniCAR) targeting CD123-positive AML
por: Meyer, Jan-Erik, et al.
Publicado: (2021)

Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML)
por: Hofmann, Susanne, et al.
Publicado: (2019)

Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML
por: Nixdorf, D., et al.
Publicado: (2023)

Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1
por: Mabe, Nathaniel W., et al.
Publicado: (2022)

A Bump in the Road: How the Hostile AML Microenvironment Affects CAR T Cell Therapy
por: Epperly, Rebecca, et al.
Publicado: (2020)

Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients
por: Marofi, Faroogh, et al.
Publicado: (2021)

Rapamycin Pretreatment Rescues the Bone Marrow AML Cell Elimination Capacity of CAR-T Cells
por: Nian, Zhigang, et al.
Publicado: (2021)

Recent Advances in the Development of Anti-FLT3 CAR T-Cell Therapies for Treatment of AML
por: Pedersen, Maya Graham, et al.
Publicado: (2022)

Immunotherapy of Neuroblastoma: Facts and Hopes
por: Anderson, John, et al.
Publicado: (2022)

Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts
por: Cartellieri, M, et al.
Publicado: (2016)

Loss of the tumor suppressor Hace1 leads to ROS-dependent glutamine addiction
por: Cetinbas, Naniye, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_k7i19c2h3nfg6kb7at258qb2ah